Conference call with MediWound management and U.S. key opinion leader begins today, January 22, 2019 at 10:00 a.m. Eastern time YAVNE, Israel, Jan. 22, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd.

YAVNE, Israel, Sept. 16, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “MediWound”), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in ...

NexoBrid is a topically administered, bromelain-based biological product containing a sterile mixture of proteolytic enzymes. The Food and Drug Administration (FDA) has issued a Complete Response ...

CAMBRIDGE, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the U.S.

Potential to become the new standard of care for eschar removal in patients with deep partial- and/or full- thickness thermal burns Triggers $7.5 million milestone payment from Vericel Corporation ...

Pivotal U.S. Phase 3 Clinical Study Met Primary and All Secondary Endpoints Highly Synergistic with Existing Commercial Franchise and Significantly Expands Vericel’s Presence in the Severe Burn Care ...

NexoBrid is a topically administered, bromelain-based biological product containing a sterile mixture of proteolytic enzymes. The Food and Drug Administration (FDA) has expanded the approval of ...

Please provide your email address to receive an email when new articles are posted on . Phase 3 data shows NexoBrid allows for the early complete eschar removal in more than 90% of patients. This ...

YAVNE, Israel, May 04, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet medical needs in severe burn ...

CAMBRIDGE, Mass., June 30, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ: VCEL) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration ...